Holen Sie sich die Stockscreener-App
3.59
3.49%
-0.13
Schlusskurs vom Vortag:
$3.72
Offen:
$3.71
24-Stunden-Volumen:
3.44M
Relative Volume:
1.64
Marktkapitalisierung:
$1.02B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-125.04M
KGV:
-4.378
EPS:
-0.82
Netto-Cashflow:
$-122.99M
1W Leistung:
+3.16%
1M Leistung:
+24.22%
6M Leistung:
+147.59%
1J Leistung:
+32.96%
1-Tages-Spanne:
$3.555
$3.745
1-Wochen-Bereich:
$3.39
$3.77
52-Wochen-Spanne:
$1.01
$3.80
Erasca Inc Stock (ERAS) Company Profile
Firmenname
Erasca Inc
Sektor
Branche
Telefon
(858) 465-6511
Adresse
3115 MERRYFIELD ROW, SAN DIEGO
Vergleichen Sie ERAS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ERAS
Erasca Inc
|
3.59 | 1.06B | 0 | -125.04M | -122.99M | -0.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Erasca Inc Stock (ERAS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-16 | Eingeleitet | Stifel | Buy |
| 2025-09-03 | Herabstufung | BofA Securities | Buy → Underperform |
| 2025-08-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-03-26 | Eingeleitet | Raymond James | Outperform |
| 2024-11-18 | Eingeleitet | Jefferies | Buy |
| 2024-03-11 | Eingeleitet | CapitalOne | Overweight |
| 2024-01-05 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-10-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-03-30 | Eingeleitet | Mizuho | Buy |
| 2023-02-24 | Eingeleitet | Goldman | Buy |
| 2023-02-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
Alle ansehen
Erasca Inc Aktie (ERAS) Neueste Nachrichten
Erasca (NASDAQ:ERAS) Trading Up 4.1% – Should You Buy? - Defense World
Aug Spikes: How Erasca Inc stock responds to policy changesJuly 2025 Drop Watch & Low Risk Growth Stock Ideas - moha.gov.vn
Erasca (ERAS) Valuation Check After S&P Biotechnology Select Industry Index Inclusion - Yahoo Finance
Did Index Inclusion and New RAS Patent Just Shift Erasca's (ERAS) Investment Narrative? - simplywall.st
Erasca, Inc.(NasdaqGS: ERAS) added to S&P Biotechnology Select Industry Index - marketscreener.com
Treasury Yields: Is Erasca Inc stock a buy on dipsWeekly Profit Summary & AI Powered Market Entry Strategies - moha.gov.vn
Why Erasca Inc. stock could be next big winnerWeekly Loss Report & Stock Portfolio Risk Management - Улправда
Will Erasca Inc. stock remain a Wall Street favoritePortfolio Update Summary & Risk Controlled Swing Trade Alerts - Улправда
Buyback Watch: Is Erasca Inc. stock a buy on dipsMarket Activity Summary & Daily Chart Pattern Signals - DonanımHaber
Aug Weekly: How Erasca Inc. stock responds to policy changesJuly 2025 Momentum & Free Long-Term Investment Growth Plans - DonanımHaber
Momentum Shift: Why Erasca Inc. stock could be next big winner2025 Geopolitical Influence & Comprehensive Market Scan Reports - Улправда
Erasca (ERAS) Valuation Check After ERAS-0015 Patent Extension and New Chief Scientific Officer Appointment - simplywall.st
Erasca Inc stock hits 52-week high at $3.68 - Investing.com India
Shareholder Erasca Foundation Files To Sell 8,333 Of Erasca Inc [ERAS] - TradingView — Track All Markets
Erasca Inc stock hits 52-week high at $3.68 By Investing.com - Investing.com Nigeria
Erasca (ERAS) Extends ERAS-0015 Patent to 2043 and Strengthens RAS Pipeline Momentum - simplywall.st
Discovering Opportunities: AirJoule Technologies Among 3 Promising Penny Stocks - simplywall.st
Erasca price target raised to $5 from $4 at Mizuho - MSN
Aug Breakouts: Is Erasca Inc stock a buy for dividend growthEarnings Growth Report & AI Optimized Trading Strategy Guides - moha.gov.vn
Analyst Confidence High in Erasca (ERAS) Amid Pipeline Advancement and Earlier Q3 2025 Results - MSN
Platform Technologies Drive $211B Surge in Precision Cancer Treatment - marketscreener.com
Erasca, Inc Secures U.S. Patent Protection Through 2043 for ERAS-0015 - marketscreener.com
Mizuho Maintains Erasca (ERAS) Outperform Recommendation - Nasdaq
Check Out Erasca Inc (ERAS)’s Trade Data Rather Than the Analysts’ Views - Setenews
Mizuho raises Erasca stock price target to $5 on RAS space optimism - Investing.com Canada
Mizuho raises Erasca stock price target to $5 on RAS space optimism By Investing.com - Investing.com South Africa
Mizuho Raises Price Target on Erasca to $5 From $4, Keeps Outperform Rating - marketscreener.com
Erasca, Inc. (NASDAQ:ERAS) Given Average Rating of "Hold" by Analysts - MarketBeat
Affinity Asset Advisors LLC Grows Stock Holdings in Erasca, Inc. $ERAS - Defense World
Will Erasca Inc. stock outperform international peers2025 Top Gainers & Fast Gaining Stock Reports - Newser
Gitlab, Acadia Healthcare, Box And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Sahm
Moving Averages: Why Erasca Inc. stock could be next big winnerInsider Buying & Momentum Based Trading Signals - moha.gov.vn
Unusually active option classes on open October 8th - MSN
Erasca to Present at the 8th Annual Evercore Healthcare Conference - The Manila Times
Adversity is less terrifying than hope: Erasca Inc (ERAS) - Setenews
Understanding Erasca Inc.’s price movementPortfolio Risk Summary & High Yield Equity Trading Tips - newser.com
Will Erasca Inc. stock benefit from automation2025 Earnings Surprises & Real-Time Volume Trigger Notifications - newser.com
Erasca Inc. stock chart pattern explainedJuly 2025 Market Mood & Safe Swing Trade Setups - newser.com
Why Erasca Inc. stock remains on watchlistsWeekly Stock Analysis & Free Weekly Watchlist of Top Performers - newser.com
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B - GlobeNewswire
Finanzdaten der Erasca Inc-Aktie (ERAS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.57%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):